Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.

作者: P. Gisondi , A. Conti , G. Galdo , S. Piaserico , C. De Simone

DOI: 10.1111/BJD.12235

关键词:

摘要: Summary Background  Chronic plaque psoriasis is frequently associated with metabolic disorders including obesity. Antitumour necrosis factor α treatments can induce body-weight increase in patients psoriasis. Information on the effect of ustekinumab body weight not available. Objectives  To investigate whether therapy changes mass index (BMI) chronic psoriasis. Methods  A prospective, multicentre study comparing BMI two closed cohorts during 7-month treatment (n = 79) or infliximab (n = 83). Results  Patients treated for 7 months showed a significant (P   2%, compared only 11% those receiving (P = 0·01). In multivariate analysis, all other clinical parameters predicted increase, except use infliximab. At month 7, 96% and 82% achieved at least 50% improvement from their baseline area severity (PASI 50), 69% group 58% PASI 75. There was no difference proportion 50 75 responders between groups. Conclusions  contrast to infliximab, does This could be taken into account selection biologics when treating

参考文章(15)
V. Florin, A.C. Cottencin, E. Delaporte, D. Staumont-Sallé, Body weight increment in patients treated with infliximab for plaque psoriasis. Journal of The European Academy of Dermatology and Venereology. ,vol. 27, ,(2013) , 10.1111/J.1468-3083.2012.04571.X
LAURA DI RENZO, ROSITA SARACENO, CATERINA SCHIPANI, MARIAGIOVANNA RIZZO, ALESSIA BIANCHI, ANNALISA NOCE, MARIA ESPOSITO, SERGIO TIBERTI, SERGIO CHIMENTI, ANTONINO DE LORENZO, Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatologic Therapy. ,vol. 24, pp. 446- 451 ,(2011) , 10.1111/J.1529-8019.2011.01439.X
A.B. Kimball, K.B. Gordon, S. Fakharzadeh, N. Yeilding, P.O. Szapary, B. Schenkel, C. Guzzo, S. Li, K.A. Papp, Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. British Journal of Dermatology. ,vol. 166, pp. 861- 872 ,(2012) , 10.1111/J.1365-2133.2012.10901.X
Paolo Gisondi, Micol Del Giglio, Vincenzo Di Francesco, Mauro Zamboni, Giampiero Girolomoni, Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. The American Journal of Clinical Nutrition. ,vol. 88, pp. 1242- 1247 ,(2008) , 10.3945/AJCN.2008.26427
R SARACENO, C SCHIPANI, A MAZZOTTA, M ESPOSITO, L DIRENZO, A DELORENZO, S CHIMENTI, Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis Pharmacological Research. ,vol. 57, pp. 290- 295 ,(2008) , 10.1016/J.PHRS.2008.02.006
Micol Del Giglio, Paolo Gisondi, Gianpaolo Tessari, Giampiero Girolomoni, Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: a randomized, investigator-blinded study. Dermatology. ,vol. 224, pp. 31- 37 ,(2012) , 10.1159/000335566
E.W. Hossler, G.C. Wood, C.D. Still, C.M. Mowad, M.S. Maroon, The effect of weight loss surgery on the severity of psoriasis British Journal of Dermatology. ,vol. 168, pp. 660- 661 ,(2013) , 10.1111/J.1365-2133.2012.11211.X
Thorvardur Jon Love, Yanyan Zhu, Yuqing Zhang, Lindsay Wall-Burns, Alexis Ogdie, Joel M Gelfand, Hyon K Choi, Obesity and the risk of psoriatic arthritis: a population-based study Annals of the Rheumatic Diseases. ,vol. 71, pp. 1273- 1277 ,(2012) , 10.1136/ANNRHEUMDIS-2012-201299
P. Gisondi, G. Tessari, A. Conti, S. Piaserico, S. Schianchi, A. Peserico, A. Giannetti, G. Girolomoni, Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study British Journal of Dermatology. ,vol. 157, pp. 68- 73 ,(2007) , 10.1111/J.1365-2133.2007.07986.X